Peptides Similar to Ipamorelin

Peptides Related to Ipamorelin#

Several peptides share functional overlap with Ipamorelin in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

Objective status: We defined the scope, searched and extracted evidence for Ipamorelin, TB-500/Thymosin β4, and GHK-Cu, explicitly sought head-to-head data, and synthesized findings into a comparative table. No direct head-to-head clinical trials among these peptides were found. Below we provide a concise, evidence-based comparison with citations.

Comparative synthesis

Ipamorelin. Clinical development for gastrointestinal motility failed to demonstrate efficacy. Phase II randomized placebo-controlled studies for postoperative ileus did not shorten time to first meal or improve measurable colonic functions versus placebo; development was discontinued. This indicates lack of clinical efficacy for the intended GI indication despite a favorable mechanistic rationale as a ghrelin receptor agonist (GHS). In contrast, preclinical work in a rat postoperative ileus model showed that ipamorelin reduced colonic transit time after surgery and, with repeated dosing over 48 hours, increased cumulative fecal output and food intake—functional outcomes that support biological activity but did not translate in Phase II trials.

Thymosin β4 (TB-500). Human randomized evidence exists in ophthalmology. In a Phase II, double-masked, placebo-controlled study of 0.1% thymosin β4 ophthalmic solution (RGN-259) for moderate–severe dry eye using a controlled adverse environment model (n=72), primary endpoints (ocular discomfort and inferior corneal staining at day 29) were not met, but several secondary endpoints improved (central/superior corneal staining, reduced CAE discomfort on day 28). No adverse events were reported, suggesting an acceptable short-term safety profile; nevertheless, efficacy remains modest and endpoint-dependent. Beyond this, the clinical literature is composed of small trials or uncontrolled studies in neurotrophic keratopathy and other ocular surface diseases, while extensive animal data support corneal and dermal wound healing, angiogenesis, and anti-inflammatory effects.

GHK-Cu. Human randomized/controlled data are sparse and generally small, mostly in topical dermatology/cosmetic settings, with variable outcomes on skin firmness, wrinkles, or barrier function; robust large-scale RCTs are lacking. Preclinical evidence is broad: in diabetic and healthy rodent wound models, GHK-Cu accelerates contraction and collagen deposition; in rabbits, topical GHK improves granulation; and intra-articular GHK-Cu transiently improves graft stiffness and reduces knee laxity after ACL reconstruction in mice, though effects are not durable after cessation and do not improve ultimate load-to-failure or gait. Regulatory notes: while topical products are in use, injectable GHK-Cu has been placed on an FDA list of Bulk Drug Substances that Raise Significant Safety Risks (concerns include impurities and immune reactions), which has stalled injectable clinical development.

Head-to-head evidence. We found no direct comparative clinical trials of ipamorelin versus thymosin β4/TB-500, ipamorelin versus GHK-Cu, or GHK-Cu versus thymosin β4. Available human studies for ipamorelin and thymosin β4 are placebo-controlled within their indications; GHK-Cu human data are largely cosmetic and not directly comparable.

Overall comparative efficacy assessment

• Strength of human clinical evidence: Thymosin β4 has the most tangible human RCT signal (dry eye) but with missed primaries and positive secondaries; ipamorelin’s GI indication failed in Phase II; GHK-Cu lacks robust RCTs in target repair indications. Thus, none demonstrates strong, consistent efficacy in rigorous head-to-head or large RCTs for tissue repair indications considered here.
• Translational gap: All three show preclinical efficacy aligned with proposed mechanisms (ghrelinergic prokinetic effects; Tβ4’s actin-binding, pro-migration/angiogenic effects; GHK-Cu’s matrix remodeling and anti-inflammatory actions), but translation to clear clinical benefit is limited to modest or endpoint-specific improvements.
• Safety/regulatory: Ipamorelin development for POI was discontinued after negative efficacy; thymosin β4 ophthalmic trial reported no AEs, but broader approvals are not established; injectable GHK-Cu faces FDA safety-risk listing while topical use persists.

Implications for research and practice

• For ipamorelin, additional research would need to identify indications beyond GI motility where ghrelin receptor agonism could yield clinical benefit; current evidence does not support efficacy for POI.
• For thymosin β4, further adequately powered, endpoint-rigorous RCTs in ocular surface disease and dermal wounds are required to confirm clinical benefit beyond secondary endpoints.
• For GHK-Cu, controlled human trials in wound healing with robust functional endpoints, optimized delivery (to overcome rapid degradation), and standardized formulations are needed; injectable routes face regulatory barriers.

Across these peptides, preclinical data are encouraging, but clinical efficacy remains limited or inconsistent, and no head-to-head trials exist. Thymosin β4 currently has the most suggestive human RCT signal (secondary endpoints in dry eye), ipamorelin failed for POI in Phase II despite positive preclinical motility data, and GHK-Cu shows promising preclinical wound biology but lacks large, rigorous human trials and faces injectable regulatory constraints.

Mechanism Comparison#

• Overlapping mechanisms: ghrelin, GHRP‑2, GHRP‑6, hexarelin, macimorelin, and anamorelin all share ipamorelin’s primary target (GHS‑R1a) and its canonical PLC/IP3/Ca2+ signaling, with access to β‑arrestin/Src‑mediated ERK/Akt pathways.
• Key differences: ipamorelin is distinguished by GH‑selective endocrine output; ghrelin and earlier GHRPs more commonly activate the HPA axis and prolactin; hexarelin/GHRP‑6 also act at CD36 to drive PI3K/Akt cardioprotection; macimorelin is primarily used as a diagnostic GH stimulus; anamorelin has prominent orexigenic activity and may elevate ACTH in some contexts.

Combination and Synergy#

• Synergy between a growth hormone secretagogue (GHS; ghrelin receptor agonist) and GHRH: Multiple controlled human infusion studies demonstrate synergistic GH release when a GHS (e.g., GHRP‑2) is co‑administered with GHRH, producing larger and faster GH pulses than either alone. Mechanistically, synergy is consistent with distinct intracellular pathways (GHRH→cAMP/PKA vs ghrelin/GHS→PLC–Ca2+) and differential somatostatin sensitivity, supporting complementary actions in vivo. However, these studies used GHS such as GHRP‑2/hexarelin rather than ipamorelin specifically, and they did not assess tissue‑repair endpoints.
• Ipamorelin + GHRH analogs (CJC‑1295/sermorelin/tesamorelin): No peer‑reviewed controlled co‑administration trials were identified that directly test ipamorelin with a GHRH analog for healing or body‑composition outcomes. Grey‑literature sources describe this “GH stack” as physiologically complementary (sustained GHRH‑driven tone plus GHS‑driven pulses), but these claims lack rigorous clinical validation.
• Ipamorelin + wound‑healing peptides (BPC‑157, TB‑500/thymosin β4): No published animal or human combination studies were found evaluating synergy or additivity on wound/tendon/bone healing or recovery. Available ipamorelin data in healing contexts are monotherapy only.
• Relevant monotherapy context: Ipamorelin alone improves postoperative ileus outcomes in rodents and showed signals in a proof‑of‑concept human trial, and increases bone mineral content in adult female rats. These support potential roles in recovery or anabolic effects but do not establish combination synergy.

Key details and evidence

• Human synergy evidence for GHS + GHRH (not ipamorelin‑specific): Co‑infusion studies reported a ~54‑fold increase in pulsatile GH vs control with GHRP‑2 + GHRH (vs 20‑fold with GHRH alone), and a ~43% shorter time‑to‑peak GH, indicating synergy. Reviews attribute this to complementary receptor signaling and modulation of endogenous GHRH and somatostatin. Tissue‑repair endpoints were not measured.
• Ipamorelin with GHRH analogs (CJC‑1295/sermorelin): Reviews summarize that CJC‑1295 can sustain GH/IGF‑1 elevations and that ipamorelin produces pulsatile GH with selectivity, yielding a plausible complementary mechanism. Yet, no controlled co‑administration trials with clinical endpoints or quantified GH/IGF‑1 synergy were identified; claims are largely anecdotal.
• Ipamorelin with BPC‑157 or TB‑500: The literature surveyed did not reveal peer‑reviewed co‑administration studies. Assertions of enhanced tendon/ligament repair or wound healing with such stacks remain unverified by controlled data.
• Ipamorelin monotherapy in healing contexts: In a rodent postoperative ileus model, ipamorelin improved GI transit; a human proof‑of‑concept RCT suggested benefit signals in GI recovery. Separately, ipamorelin (and GHRP‑6) increased bone mineral content in rats; effects reflected increased bone size rather than volumetric BMD changes. These studies do not involve combinations.

Implications

• The best existing evidence for synergy is class‑based: ghrelin‑pathway GHS + GHRH show synergistic GH release in humans, which could, in principle, extend to ipamorelin + GHRH analogs. Nevertheless, there is a current lack of ipamorelin‑specific co‑administration trials demonstrating synergistic or complementary effects on GH/IGF‑1 or healing endpoints, and no published data for ipamorelin combined with BPC‑157 or TB‑500.

Practice and research gaps

• Clinical trials directly testing ipamorelin + GHRH analogs against monotherapy arms with GH/IGF‑1 dynamics and prespecified healing/tissue endpoints are needed. Similarly, controlled animal or human studies of ipamorelin with BPC‑157 or TB‑500 evaluating tendon, wound, or bone repair would be required to substantiate synergy claims.

Embedded summary table

Evidence Gaps#

Direct head-to-head comparison studies between Ipamorelin and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• Ipamorelin overview and research guide
• Ipamorelin research evidence
• Ipamorelin dosing protocols